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Abstract: BACKGROUND The incidence and magnitude of cardiac ischemia and arrhythmias in patients
with chronic obstructive pulmonary disease (COPD) during exposure to hypobaric hypoxia is insufficiently
studied. We investigated electrocardiogram (ECG) markers of ischemia at rest and during incremental
exercise testing (IET) in COPD-patients travelling to 3100 m. STUDY DESIGN AND METHODS
Lowlanders (residence <800 m) with COPD (forced volume in the first second of expiration (FEV1)
40-80% predicted, oxygen saturation (SpO2) ฀92%, arterial partial pressure of carbon dioxide (PaCO2)
<6 kPa at 760 m) aged 18 to 75 years, without history of cardiovascular disease underwent 12‑lead ECG
recordings at rest and during cycle IET to exhaustion at 760 m and after acute exposure of 3 h to 3100
m. Mean ST-changes in ECGs averaged over 10s were analyzed for signs of ischemia (฀1 mm horizontal
or downsloping ST-segment depression) at rest, peak exercise and 2-min recovery. RESULTS 80 COPD-
patients (51% women, mean ± SD, 56.2 ± 9.6 years, body mass index (BMI) 27.0 ± 4.5 kg/m2, SpO2
94 ± 2%, FEV1 63 ± 10% prEd.) were included. At 3100 m, 2 of 53 (3.8%) patients revealed ฀1 mm
horizontal ST-depression during IET vs 0 of 64 at 760 m (p = 0.203). Multivariable mixed regression
revealed minor but significant ST-depressions associated with altitude, peak exercise or recovery and rate
pressure product (RPP) in multiple leads. CONCLUSION In this study, ECG recordings at rest and
during IET in COPD-patients do not suggest an increased incidence of signs of ischemia with ascent to
3100 m. Whether statistically significant ST changes below the standard threshold of clinical relevance
detected in multiple leads reflect a risk of ischemia during prolonged exposure remains to be elucidated.
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Background: The incidence andmagnitude of cardiac ischemia and arrhythmias in patients with chronic obstruc-
tive pulmonary disease (COPD) during exposure to hypobaric hypoxia is insufficiently studied. We investigated
electrocardiogram (ECG) markers of ischemia at rest and during incremental exercise testing (IET) in COPD-
patients travelling to 3100 m.
Study design and methods: Lowlanders (residence <800 m) with COPD (forced volume in the first second of ex-
piration (FEV1) 40–80% predicted, oxygen saturation (SpO2) ≥92%, arterial partial pressure of carbon dioxide
(PaCO2) <6 kPa at 760 m) aged 18 to 75 years, without history of cardiovascular disease underwent 12‑lead
ECG recordings at rest and during cycle IET to exhaustion at 760 m and after acute exposure of 3 h to 3100 m.
Mean ST-changes in ECGs averaged over 10s were analyzed for signs of ischemia (≥1 mm horizontal or
downsloping ST-segment depression) at rest, peak exercise and 2-min recovery.
Results: 80 COPD-patients (51% women, mean± SD, 56.2± 9.6 years, body mass index (BMI) 27.0± 4.5 kg/m2,
SpO2 94±2%, FEV1 63±10% prEd.)were included. At 3100m, 2 of 53 (3.8%) patients revealed ≥1mmhorizontal
ST-depression during IET vs 0 of 64 at 760m (p=0.203).Multivariablemixed regression revealedminor but sig-
nificant ST-depressions associated with altitude, peak exercise or recovery and rate pressure product (RPP) in
multiple leads.
Conclusion: In this study, ECG recordings at rest and during IET in COPD-patients do not suggest an increased in-
cidence of signs of ischemia with ascent to 3100 m. Whether statistically significant ST changes below the stan-
dard threshold of clinical relevance detected in multiple leads reflect a risk of ischemia during prolonged
exposure remains to be elucidated.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Due to increasing worldwide mobility and advances in infrastruc-
ture, a considerable number of patients with chronic obstructive
pulmonary disease (COPD) travel to high altitude. However, the safety
of altitude sojourns in COPD-patients is insufficiently known. COPD-
patients have a higher prevalence of cardiovascular diseases [1–4], in-
cluding coronary artery disease (CAD)whichmay predispose to cardiac
ischemia in a hypoxic environment. The body physiologically adapts to
altitude with increased breathing- and heart rates causing a shortening
of the diastole [5]. As cardiac perfusion mainly occurs during diastole,
the risk of cardiac ischemia may increase with altitude due to the re-
duced cardiac perfusion relative to increased myocardial oxygen con-
sumption. COPD-patients also have a lower respiratory reserve
compared to healthy, who use an increased breathing rate as a compen-
satory mechanism at altitude. COPD-patients additionally may reveal
pulmonary hypertension already at low altitude, but even more in a
hypoxic environment at high altitude, which further strains the right
ventricular reserve to ischemia, due to increased load [6,7]. The men-
tioned adaptive responses are accentuated during exercise.
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The electrocardiogram (ECG) is a well-established and widely avail-
able tool to diagnose scars and cardiac ischemia at rest and during exer-
cise. There are various studies on ECG-changes at altitude in healthy
subjects [8] but to date there are very few studies on ECG-changes in
COPD-patients exposed to hypoxia at real or simulated altitude, espe-
cially during exercise [9]. One study showed that during a high altitude
simulation test (up to 3048 m) 2 out of 22 patients with normocapnic
COPD developed asymptomatic premature atrial or ventricular contrac-
tions (PAC and PVC) [10]. Recent studies detected a significant increase
of nocturnal PVC in patients with moderate to severe COPD at 2500 m
[11] or showed a significant increase in nocturnal corrected QT interval
(QTc) in COPD-patients at 2048 m, which wasn't affected by supple-
mentary oxygen [12]. However, to our knowledge, no study has yet in-
vestigated signs of ischemia or arrhythmia on a 12‑lead ECG in COPD-
patients who travel to and perform exhaustive exercise at high altitude.
Thus, we investigated ECG-changes at rest and during incremental exer-
cise testing (IET) in COPD-patients travelling to 3100 m with focus on
signs of ischemia.
2. Methods
2.1. Study design and participants
This is a nested studywithin a larger ongoing clinical trial investigat-
ing structured self-monitoring for early signs of altitude related adverse
health events during an altitude sojourn in COPD-patients. This study
was conducted in accordancewith the amendedDeclaration of Helsinki.
The ethics committee of the National Center for Cardiology and Internal
Medicine in Bishkek, Kyrgyzstan approved the trial and all subjects pro-
vided written consent.
Male and female lowlanders born, raised and currently living at
<800 mwith moderate to severe COPD (GOLD 2&3, forced expiration
volume in the first second of expiration (FEV1) 40–80% predicted;
oxygen saturation (SpO2) ≥92%; arterial pressure of carbon dioxide
(PaCO2) <6 kPa at 760 m) between 18 and 75 years were included
in this study. Exclusion criteria were acute COPD-exacerbations,
severe COPD with hypoxemia or hypercapnia on ambient air at
760 m, history or symptoms of severe cardiovascular disease, such
as CAD, or any disease interfering with protocol compliance, including
heavy smoking (>20 cigarettes per day).
Subjects underwent baseline measurements during an initial two-
day visit in Bishkek at 760m. After a break at home (3–21days) subjects
returned to Bishkek, where baseline resting ECG and IET were per-
formed. On the next day, they were transferred by mini-bus to an alti-
tude clinic at 3100 m (Tuja Ashu, Kyrgyzstan). ECG at rest and during
IET were performed after 3 h at altitude.
2.2. Measurements
Trained study personnel obtained all measurements. At the first
visit, detailed personal history, physical examination and current med-
ication were obtained. Age, height, weight, body mass index (BMI),
blood pressure, heart rate, breathing rate and SpO2 were recorded. Par-
ticipants performed spirometry (Spirostik, Diffustik, Geratherm,
Geschwenda, Germany) according to the 2005 American Thoracic Soci-
ety/European Respiratory Society guidelines [13]. Radial artery blood
gaseswere drawn and immediately analyzed (RapidPoint 500, Siemens,
Zurich, Switzerland).
12‑lead resting ECGswere recorded electronically at 760 and 3100m
(CardioPart 12 Blue, Amedtec, Aue, Germany). Subjects were asked to
lie in a supine position for 5 min and the skin was cleaned and shaved
before applying the electrodes. Participants performed IET on an elec-
tronically braked cycle ergometer (Ergoselect 100, Geratherm,
Geschwenda, Germany) at 760 m and 3100 m. Predicted maximal
workload was automatically calculated by the software dependent on
age, gender and weight and the ramp was adjusted to achieve a test
duration of 8–12 min. IET was preceded by 2 min of rest and followed
by 2 min of recovery where patients were sitting on the bicycle.
12‑lead ECG, heart rate and SpO2 (WristOx2 3150, Nonin Medical Inc.,
Plymouth, Minnesota, USA) were continuously recorded and blood
pressure obtained every two minutes.
2.3. 12-Lead ECG analysis
Resting ECGs at 760 m and 3100 m were categorized as normal or
abnormal. ECGs were considered abnormal if they showed signs of
prior ischemia (Q-waves, T-wave inversions), bundle branch blocks,
signs of left or right ventricular hypertrophy (LVH or RVH), axis devia-
tion, conductance disturbances, prolonged QTc (>450 ms in males
and > 460ms in females, using Bazett's formula [14]) or preexisting ar-
rhythmia. PQ interval, QRS duration, and QT interval (PQ, QRS and QT)
were measured electronically (ECGpro version 4.80.007, Amedtec
GmbH, Aue, Germany).
In the exercise ECGs, three measurement time points were defined:
at rest, at peak exercise and after 2min of recovery. ST segment changes
were averaged automatically over 10 s (minimum 7 QRS complexes)
and measured electronically 80 ms after the J-point (or 60 ms in cases
of early repolarization, after visual review by the investigators). PQ,
QRS and QT were measured electronically. PAC and PVC scored manu-
ally. Single leads with significant artefacts were excluded from analysis.
Two investigators categorized all resting ECGs and manually scored the
exercise ECGs for signs of ischemia.Where opinions differed, consensus
was reached by agreement.
2.4. Outcomes
The primary outcome was the difference in proportion of ECG-signs
of clinically relevant ischemia at peak exercise (defined as ≥1 mm hori-
zontal or downsloping ST-segment depression or new T-wave inver-
sions) between 760 m and 3100 m. As the current study was nested
within a larger trial with predetermined sample size according to a
power calculation for that trial's primary outcome, no independent a
priori sample size estimation for the analysis of ST-segment changes
was performed. Nevertheless, an exploratory post-hoc assessment of
power was carried out using the observed data.
Secondary outcomes included incidence of cardiac symptoms (chest
pain, palpitations, headache, dizziness, syncope, nausea), arrhythmia,
mean ST-changes in any lead, changes in QTc, PAC and PVC per minute
during IET at 760 and 3100 m and the prevalence of abnormal resting
ECGs as described above at 760 m and 3100 m.
2.5. Statistical analysis
Final analysis included all available measurements from 760 m and
3100 m. Single missing values of secondary outcomes were not re-
placed. All statistical analyses were performed using R Studio (version
1.2.1578, R Studio Inc., San Francisco, USA). Resting ECG parameters
were compared with two-sided, paired t-tests. Resting ECG categoriza-
tions and incidences of ischemia during IET were compared using
Fisher's exact or Chi-squared tests. Analyses of ST-segment changes,
QTc, and PVC and PAC per minute were performed in a multivariable
mixed linear regression model, with altitude (760 m vs 3100 m), time
point (rest, peak exercise and 2-min recovery), sex (only for QTc),
FEV1 and rate pressure product (RPP, heart rate × systolic blood pres-
sure) as independent variables. Single leads with significant artefacts
are excluded from analysis. Continuous data are reported as mean ±
standard deviation and parameters from themultivariable mixed linear
regression models are expressed as mean change and 95% confidence
interval. A p-value threshold of <0.05 or a confidence interval not cross-
ing 0 was considered to be statistically significant.




A total of 80 patients were included in the study, consisting of a near
equal number of middle-aged men and women of normal weight, with
moderate airflow obstruction and only mild hypoxemia at 760 m.
Table 1 shows the baseline characteristics. Supplementary Fig. 1
shows the patient flow.
3.2. Resting 12-Lead ECG analysis
Resting ECG categorizations and indices at 760 m and 3100 m are
presented in Table 2. All 80 patients performed resting ECG at
760 m, of which 52 (65%) were categorized as normal and 28 (35%)
as abnormal. The most common abnormality on resting ECG at
760 m were signs of prior ischemia (16%), which presented almost
exclusively in the inferior leads, followed by QTc-prolongation (15%)
and first-degree atrioventricular (AV) block (5%). One patient with
right bundle branch block was excluded from QT/QTc analysis. At
3100 m, 66 of 80 patients underwent resting ECG, of which 43 (65%)
were categorized as normal and 23 (35%) as abnormal. As at 760 m,
the most common abnormality detected were signs of previous ische-
mia (17%) again almost exclusively presenting in the inferior leads,
followed by QT-prolongation (12%) and first-degree AV block (6%).
Abnormalities of resting ECGs seen at 760m, including signs of prior
ischemia and first-degree AV blocks, persisted at 3100 m, but were not
different in proportion or severity. PQ, QRS and QTc did not differ signif-
icantly from 760 m to 3100 m. 3 subjects with previously borderline
normal QTc at 760 m developed QTc-prolongation at 3100 m, whereas
QTc normalized in 4 subjects. 14 subjects did not undergo resting ECG
at 3100 m (Supplementary Fig. 1), of which 9 had normal ECGs at
760 m, 2 signs of previous ischemia in the inferior leads, 2 QTc-
prolongation, and one right bundle branch block.
3.3. Exercise 12-Lead ECG analysis
64 out of 80 patients (80%) performed IET including 12‑lead ECG
at 760 m. Of the 64 patients with IET at 760 m, 53 patients (66% of
total) performed IET at 3100 m (Supplementary Fig. 1). At 3100 m
2 (3.8%) patients with previously normal resting ECG revealed
≥1 mm ST-depression on exercise ECG vs 0 at 760 m (p = 0.203).
One patient with ≥1 mm ST-depression reported chest pain. No
patients developed clinically significant supraventricular or ventric-
ular arrhythmia at 760 m or 3100 m. There were significant changes
in peak workload, %-predicted workload, heart rate, RPP and SpO2 at
peak exercise between 760 m and 3100 m (Table 3).
In amultivariablemixed linear regressionmodel, multiple ECG leads
showed associations between mean ST-segment changes and altitude,
time point and combined interaction between altitude, peak exercise
and 2-min recovery (Fig. 1 and Supplementary Table 1).When adjusted
for altitude and RPP, themodel showed independent associations of RPP
with mean ST-segment changes in multiple leads (Supplementary
Table 2). However, there was no association betweenmean ST segment
changes in any lead and baseline FEV1. QTc showed an independent as-
sociation with altitude (−6(−11 to−1)ms, p=0.022)) but was inde-
pendent of sex, FEV1 and RPP. Single PAC and PVC were recorded in
some individuals, but PAC and PVC per minute did not show an associ-
ation with any of the independent variables.
Table 1
Patients' baseline characteristics at 760 m.
Baseline characteristics Mean ± SD or number (%)
Patient number 80
Men / women, n 39 (49%) / 41 (51%)
Age, years 56.2 ± 9.6
Height, cm 163 ± 9
Weight, kg 72.8 ± 14.2
BMI, kg/m2 27.0 ± 4.5
Pulmonary function tests
GOLD II / III 68 (85%) / 12 (15%)
FEV1, % predicted 63 ± 10
FVC, % predicted 87 ± 12
FEV1/FVC, % 57 ± 11
Vital parameters
Blood pressure systolic, mmHg 122 ± 12
Blood pressure diastolic, mmHg 80 ± 9
Heart rate, min−1 82 ± 11
Breathing rate, min−1 19 ± 2
SpO2, % 94 ± 2
Arterial blood gas analyses
pH 7.49 ± 0.02
PaO2, kPa 9.5 ± 1.0
PaCO2, kPa 5.5 ± 0.5
HCO3−, mmol/l 24.8 ± 2.2
Comorbidities




Inhaled beta-adrenergics 35 (44%)
Inhaled steroids 29 (36%)





Oral steroids 0 (0%)
Data are reported asmean± standard deviation (SD) or number and percentage (%). BMI:
bodymass index; FEV1: forced expiration in one second; FVC: forced vital capacity; SpO2:
oxygen saturation by pulse oximetry; PaO2: arterial oxygen partial pressure; PaCO2: arte-
rial carbon dioxide partial pressure; HCO3-: hydrogencarbonate
Table 2
Resting ECG at 760 m and 3100 m.
Resting ECG indices, ms Bishkek (760 m) Tuja Ashu (3100 m)
Mean ± SD Mean ± SD
QTc (males) 426 ± 21 430 ± 22 p = 0.374
QTc (females) 438 ± 20 438 ± 22 p = 0.525
QT (males) 387 ± 24 383 ± 22 p = 0.131
QT (females) 388 ± 20 386 ± 20 p = 0.539
PQ 162 ± 28 162 ± 28 p = 0.814
QRS 86 ± 10 88 ± 8 p = 0.167
Heart rate 82 ± 11 84 ± 12 p = 0.143




Number (%) Number (%)
Total ECGs 80 66
Patients with normal resting
ECG
52 (65%) 43 (65%)
Patients with abnormal resting
ECG
28 (35%) 23 (35%) p = 0.985
Signs of prior ischemia 13 (16%) 11 (17%) p = 0.946
of which inferior leads: 12 (15%) 10 (15%) p = 0.980
of which anterior leads: 1 (1%) 1 (2%) p = 1.000
Prolonged QTc interval 12 (15%) 8 (12%) p = 0.615
of which male (>450 ms): 5 (6%) 4 (6%) p = 1.000
of which female (>460 ms): 7 (9%) 4 (6%) p = 0.755
1st degree AV block 4 (5%) 4 (6%) p = 1.000
Right axis deviation 2 (3%) 2 (3%) p = 1.000
Left ventricular hypertrophy 1 (1%) 1 (2%) p = 1.000
Right bundle branch block 1 (1%) 0 (0%) p = 1.000
Left anterior fascicular block 1 (1%) 1 (2%) p = 1.000
Data are reported asmean± standard deviation (SD) or number and percentage (%). Rest-
ing ECG indices and categorization did not differ significantly between 760m and 3100m.
One patient with right bundle branch block was excluded from QT and QTc Interval
analysis.
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3.4. Post-hoc power calculation
An exploratory post-hoc assessment of the study's power to detect
clinically relevant ST-segment changes of >1 mm was performed
based on the number of 53 participants (after drop-outs), the observed
SD of ST-changes of 0.27 mm, accounting for multiple testing in the 12
leads over the course of 5 repeated assessments by reducing the alpha
level by a factor of 100 to 0.0005. This calculation revealed a power
to detect ST-changes >1 mm of >99% and a power of 80% to detect
ST-changes as small as 0.16 mm.
4. Discussion
This is the first study investigating ECG-signs of ischemia during
cycle exercise in a large cohort of patients with COPD travelling to
3100 m. The main finding is that patients with moderate to severe
COPD without resting hypercapnia and only mild hypoxemia at low al-
titude and no history of apparent CAD did not reveal a significantly
higher incidence of ischemia during IET at 3100m.However, amultivar-
iablemixed linear regression analysis revealed significant ST-changes of
unknown clinical relevance, associated with altitude, exercise and RPP,
but not FEV1. Additionally, we report a high prevalence of abnormal
resting ECGs, most frequently signs of previous ischemia, QTc-
prolongation and first-degree AV block, which persisted after 3 h at
3100 m. Resting ECG time indices did not change significantly at
3100 m, and there was no incidence of clinically relevant arrhythmia.
4.1. Resting 12‑lead ECG analysis
COPD-patients frequently reveal cardiovascular comorbidities, even
independently of shared risk factors [1–4] and thosewithmarkers of is-
chemia on ECG have increased risk of sudden cardiac death [15] and
higher mortality [16]. The prevalence of markers of ischemia on resting
ECG in COPD has been reported at 21% overall and at 14% in COPD-
patients without self-reported cardiovascular disease [17] and are in
line with the present study (16%), although we excluded patients with
unstable CAD. These findings indicate that COPD-patients often reveal
occult ischemic heart disease. Interestingly, the ischemic ECG-changes
found in our collective presented almost exclusively in the inferior
leads and may indicate right ventricular susceptibility to ischemia in
COPD-patients. In comparison, a study byWarnier [18] showed an over-
all frequency of CAD of 19%, with a prevalence of 7% in inferior and 4% in
anterior Q-wave myocardial infarctions. Chronically increased right
ventricular load due to pulmonary hypertension at low altitude, but
even more in a hypoxic environment at high altitude and during exer-
cise [6,7], may contribute to right sided ischemia. However, in disagree-
ment to these markers of ischemia, the only sign of chronic right
ventricular strain [19] found in our collective was isolated right axis de-
viation in 3% and right bundle branch block in 1% of subjects. With 15%,
the prevalence of QTc-prolongation in our study was higher than in
Warnier's study (9%) [18] but lower than reported by Sievi (32%) [20],
which is most probably due to different collectives with milder disease
in the first, but more severe in the latter study. Accounting for disease
severity, the frequency of QTc-prolongation found in our study is com-
parable with these previous reports [18,20].
4.2. Exercise 12‑lead ECG analysis
To our knowledge, evidence on ischemic ECG-changes in COPD-
patients at altitude is very scarce. A study by Graham [9] with repeated
ECGs at rest and during treadmill exercise, showed ‘no cardiac irregular-
ities in 8 patients with moderate COPD during a three day sojourn at
1920m. Other studieswith ECG during simulated altitude [10] and dur-
ing nights at altitude [11,12] did not report signs of ischemia. The pres-
ently investigated COPD-patients did not reveal a higher incidence of
ischemia defined as horizontal or downsloping ST-segment depression
≥1 mm during IET at 3100 m compared to 760 m. However, in a
mixed linear regression model, statistically significant ST-depression
in relation to acute altitude exposure was predominantly detected in
the lateral precordial leads, whereas significant ST-depression during
exercise was predominantly detected in the inferior leads. Moreover,
when adjusted for the RPP, the regression models showed a significant
associationwith altitude in both the inferior and lateral precordial leads.
Although the number of leads with exercise-induced ST-depression is
associated with the size of ischemic area, it is not clear whether the re-
gion of affected ECG‑leads reflect the location of cardiac ischemia [21].
Significant additive effects of exercise and altitude exposure on ST-
depression, compared to the single factors exercise or altitude were
also detected, again mostly in the lateral precordial leads (Fig. 1).
Whether these significant butminor ST-changes reflect early signs of is-
chemia is unknown. One study reported that exercise-induced ST-
depression in patients without known CAD did not predict future coro-
nary events [22] but it is unclear whether the same applies for COPD-
patients, who have increased risk of cardiovascular comorbidity. The
presently investigated COPD-patients reached significantly lower abso-
lute and %-predicted workloads at 3100 m compared to 760 m. On the
other hand, they also attained significantly higher RPP and HR levels
and lower SpO2 levels at peak exercise at 3100 m, which may indicate
that the ischemic stimulus was at least comparable at high altitude.
In contrast to COPD, several studies investigated exercise ECGs- in
patients with CAD at altitude. A study by Levine showed that 10 out of
20 veterans with manifest or high risk for CAD revealed clinically rel-
evant ST-depression upon acute exposure to 2500 m on resting ECG,
Table 3
Incremental Exercise Testing at 760 and 3100 m.






Mean ± SD Mean ± SD
Peak workload, W 100 ± 28 92 ± 22 p < 0.001
Workload, % predicted 74 ± 14 68 ± 11 p < 0.001
Heart rate, min−1 131 ± 16 139 ± 17 p < 0.001

















































Palpitations 0 0 1
(2%)
0












Leg or knee pain 0 0 2
(4%)
0
Data are reported as mean ± standard deviation (SD) or number and percentage (%).
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but not during exercise or after acclimatization, and echocardiogra-
phy directly after exercise did not reveal new motion abnormalities
at altitude [23]. A study in 22 low-risk CAD-patients revascularised
after myocardial infarction and with normal IET at low altitude, did
not reveal ischemia or arrhythmia during IET at 3500 m [24]. Accord-
ingly, a literature review concluded that high altitude exposure in pa-
tients with stable CAD is relatively safe, with none of the studies
reporting ischemia at rest or during exercise upon short-term expo-
sure to moderate to high altitudes between 2500 and 3500 m [25].
Additionally, studies at varying levels of altitude in patients with ar-
terial hypertension [26], metabolic syndrome [27] and congestive
heart failure [28], all common comorbidities in COPD [1–4], did not
report ischemic ECG-changes.
4.3. Arrhythmia and QTc interval
In healthy subjects, PAC and PVC constitute the most frequently re-
ported arrhythmia at altitude but the relationship between PVC and
life-threatening ventricular arrhythmia remains inconclusive [8]. It is
well established that COPD-patients have increased cardiac arrhythmias
[18,29–31], including supraventricular tachyarrhythmia such as atrial
fibrillation, atrial flutter and multifocal atrial tachycardia [30] and the
severity of COPD is independently associated with atrial fibrillation,
non-sustained and sustained ventricular arrhythmia [30] indepen-
dently of left ventricular function [31]. There are few reports on arrhyth-
mia in COPD-patients at altitude, with the exception of increased
nocturnal PAC and PVC at 2590m [11]. In our study, we did not observe
clinically relevant arrhythmias and occasional PAC or PVC were not in-
creased with altitude or exercise, however, our total ECG-observation
time was relatively short.
Prolonged QTc is considered a risk factor for ventricular arrhythmia,
particularly for torsade de pointes [32]. QTc-prolongation has been ob-
served in hypoxemic COPD-patients [33] and during acute COPD-
exacerbation and was associated with increased mortality [34] and
may be related to hypoxia [20]. Our study did not find a significant
change of QTc from 760m to 3100m. Interestingly, in themultivariable
mixed linear regression model, QTc duration even decreased at altitude
independently of exercise. These findings contrast with a recent study
by Bisang [12], which demonstrated a significant, albeit not clinically
relevant QTc-prolongation during nocturnal measurements at 2048 m
in a comparable COPD-patient collective. However, in that study [12]
the duration of exposure to hypoxia was longer compared to our
study. This may indicate that QTc-prolongation needs longer altitude
exposure and/or is more frequently found during sleep. Nocturnal
QTc-prolongation was also found in patients with obstructive sleep
apnea at 2590 m [35]. In another study in patients with obstructive
sleep apnea, endothelial dysfunction, presumably induced by intermit-
tent hypoxia, was improved by nocturnal continuous positive airway
pressure (CPAP) therapy [36].
Retrospective studies by Nilsson and Armstrong found associations
between severity of COPD and QTc-prolongation [37,38] and frequency
of ischemic changes on resting ECG [39]. In contrast, none of the ECG in-
dices in our study, including QT and QTc, showed an association with
exercise or disease severity as expressed by FEV1.
Fig. 1. Mean ST-segment changes at rest and during exercise: Mean ST-segment changes (95% confidence interval) at rest and during exercise are shown for each lead of a 12- ECG as
calculated by multivariable mixed linear regression model with A: representing changes with altitude (from 760 m to 3100 m), P: changes from rest to peak exercise. A*P: represents
the additive changes of peak exercise from rest at altitude (3100 m), Significant changes (p < 0.05) are denoted with *.
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4.4. Limitations
This study has the following limitations: we investigated COPD-
patients at rest and IET three hours after arrival at 3100m. Future stud-
ies might include repeated ECGs at rest and exercise during prolonged
sojourns at high altitude to determine whether clinically significant is-
chemia develops. Some patients did not perform IET at 3100 m because
they developed relevant hypoxemia or symptoms and descended back
to 760 m according to safety criteria. This may have introduced a selec-
tion bias, as it is possible that these subjects would have manifested is-
chemia at rest or during IET. An exploratory post-hoc analysis revealed
that this studywas highly (>99%) powered to detectmean clinically rel-
evant ST-changes of 1 mm and even powered with 80% to detect much
smaller mean ST-changes of 0.16 mm.While our data may suggest that
exposure to hypoxia at altitude did not induce significantmyocardial is-
chemia in the studied patients as a group, we strongly caution against
concluding that clinically relevant myocardial ischemia is unlikely to
occur in an individual patient in the setting of our study. Nevertheless,
our observations represent a valuable basis for designing future, much
larger studies that will be required to evaluate the risks of cardiac ische-
mic events in COPDpatients going to high altitude. Technical limitations
included some unavoidable movement artefacts in the extremity leads,
which led to exclusion of some leads in some individuals, and the de-
pendency on the accuracy of the ECG software for the measurement
and averaging of ECG indices over 10 s.
5. Conclusion
This study investigating ECG-changes at rest and during exercise in
COPD-patients travelling to 3100 m did not reveal an increased inci-
dence of signs of ischemia nor arrhythmia. However, statistically signif-
icant ST-depressions below the threshold of clinical relevance were
detected in multiple leads. It remains to be investigated, whether
these subclinical ST-depressions reflect early signs of ischemia and
whether ST-changes would increase upon longer stays at altitude,
upon exposure to higher altitude or in more severe COPD.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.09.055.
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